GLP-1 and GLP-2 are different gut hormones with different jobs. GLP-1 receptor agonists are used in prescription treatment for obesity and type 2 diabetes, while GLP-2 therapies are used for specific intestinal conditions rather than weight loss.10 Tirzepatide is not GLP-2: it activates GIP and GLP-1 receptors.2
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the difference between GLP-1 and GLP-2 for weight loss?
The short answer: GLP-1 and GLP-2 have different primary roles. GLP-1 signaling is relevant to appetite, blood sugar, and weight management. GLP-2 signaling is focused on the intestine.10 A GLP-2 medicine should not be described as a standard weight-loss medication.10
| Feature | GLP-1 | GLP-2 |
|---|---|---|
| Full name | Glucagon-like peptide-1 | Glucagon-like peptide-2 |
| Main body role | Appetite regulation, glucose-dependent insulin secretion, and slower gastric emptying.6 | Supports intestinal lining, intestinal blood flow, and nutrient absorption.10 |
| Examples of medicines | Semaglutide; tirzepatide also acts at the GLP-1 receptor.12 | Teduglutide |
| Typical clinical use | Type 2 diabetes and, for specific FDA-approved products, chronic weight management.16 | Specific intestinal conditions, including short bowel syndrome.10 |
| Role in weight management | Supported by randomized trials for studied GLP-1-based medicines.12 | Not an established weight-loss treatment.10 |
Both hormones are made in the gut, which is why the names sound alike. But similar names do not make them interchangeable. For a broader comparison of medicines used in diabetes and weight care, see our guide to semaglutide, tirzepatide, and metformin.
What does GLP-1 do in the body?
GLP-1 works through several metabolic signals at once. It can increase fullness, slow gastric emptying, and help the pancreas release insulin when glucose is elevated. These linked effects help explain why GLP-1 receptor agonists are used in type 2 diabetes and weight-management care.6
What GLP-1 receptor agonists are
GLP-1 receptor agonists are medicines that activate the GLP-1 receptor. Semaglutide is the active ingredient in Wegovy and Ozempic; those brand products have different FDA-approved indications.1 In the STEP 2 randomized trial, participants with type 2 diabetes and overweight or obesity received 2.4 mg semaglutide once weekly as part of the study design.1
The evidence is meaningful, but it is not a promise for an individual. Different GLP-1 agents can differ in weight effect, tolerability, administration, and glucose effects.5 Common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. A clinician should also review a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, and personal or family history of medullary thyroid carcinoma or MEN2 before choosing a GLP-1-based medicine.6
Semaglutide and weight management
Semaglutide is a GLP-1 receptor agonist, not “GLP-1 itself.”6 In clinical studies, it has been evaluated alongside nutrition and activity changes. Trial outcomes can differ from everyday outcomes because persistence, dose reached, health conditions, access, and follow-up vary. The STEP 1 extension also found weight regain after semaglutide withdrawal, showing why long-term planning matters.3 Individual results vary.
What does GLP-2 do in the body?
GLP-2 is primarily an intestinal hormone, not an appetite medication. It supports the structure and function of the intestinal tract.10 That is why GLP-2-based therapy is associated with specialist treatment of certain intestinal conditions, including short bowel syndrome, rather than obesity care.10
Why GLP-2 should not be described as a weight-loss medication
A person may see “GLP-2” online and assume it means a stronger or newer version of GLP-1. That is inaccurate. GLP-2 does not describe a second-generation appetite drug, and there is no established role for GLP-2 medicines as routine treatment for obesity.10 GLP-2 medicines are not established for weight loss.10 Using a prescription medicine outside its approved indication requires an indication-specific clinician assessment.
GLP-2 medicines and intestinal conditions
Teduglutide is a GLP-2 analogue used in care for short bowel syndrome, a condition in which reduced intestinal length can limit fluid and nutrient absorption.10 That clinical goal is very different from appetite regulation. Patients with intestinal disease may need specialized monitoring because their risks, medicines, nutrition needs, and surgical history can be complex.
Is tirzepatide a GLP-1 or GLP-2 medication?
Tirzepatide is a dual GIP and GLP-1 receptor agonist—not a GLP-2 medicine. GIP means glucose-dependent insulinotropic polypeptide. “Dual agonist” refers to two receptor targets: GIP and GLP-1.2
Tirzepatide is the active ingredient in Zepbound and Mounjaro, which have different FDA-approved uses.2 In the SURPASS-2 randomized trial in adults with type 2 diabetes, tirzepatide and semaglutide were compared as once-weekly study treatments.2 That trial does not establish that one medication is right for every person or that results from branded study products apply to compounded formulations.
Like GLP-1 receptor agonists, tirzepatide can cause gastrointestinal side effects, including nausea, diarrhea, vomiting, constipation, and abdominal pain.2 The same careful review of relevant medical history is important. Our detailed Ozempic, Wegovy, Mounjaro, and Zepbound comparison explains why the names, approved uses, and active ingredients should not be mixed together.
Which medications have evidence for weight management?
Randomized trials support certain GLP-1-based medicines for weight management, but not GLP-2 medicines. Trial findings are useful for comparing studied interventions, yet they cannot predict one person’s response, side effects, affordability, or ability to stay on treatment.
| Medicine type | Weight-management evidence | Key limitation to remember |
|---|---|---|
| Semaglutide, a GLP-1 receptor agonist | Studied in randomized obesity trials, including STEP 2 in people with type 2 diabetes.1 | Study results apply to the studied product and population; individual results vary. |
| Tirzepatide, a GIP/GLP-1 dual agonist | Studied in randomized trials, including comparisons with semaglutide in type 2 diabetes.2 | A comparison trial is not a universal ranking for every patient. |
| GLP-2 analogue therapy | Used for specified intestinal conditions.10 | It is not established treatment for obesity or routine weight loss.10 |
Medication selection is not a contest for the largest average number. A clinician weighs the intended use, other health conditions, current medicines, contraindications, side-effect tolerance, and follow-up plan. Exercise also remains important: a randomized trial evaluated exercise combined with GLP-1 receptor agonist treatment for metabolic and abdominal-obesity outcomes.4
If safety is your main concern, our guide to weight-loss medication safety can help you prepare better questions for a clinical visit.
3-min quiz
Explore clinician-guided GLP-1 care
At Chia, eligible adults can complete an online health questionnaire for review by a licensed US provider. A prescription requires a medical evaluation and is never guaranteed. Our semaglutide and tirzepatide treatments are compounded by state-licensed 503A pharmacies and shipped to the door. Compounded drugs are not FDA-approved.
Can GLP-1 and GLP-2 medicines be taken together?
Do not add a GLP-2 medicine for weight loss without specialist guidance. GLP-2 medicines are not established for weight loss, and these medicines have different approved purposes.10 A combination may introduce indication-specific risks, monitoring needs, and medication-management questions that cannot be answered by a general online comparison.10
A clinician needs to know why each medicine is being considered, whether there is intestinal disease, what other prescriptions are involved, and whether there are symptoms such as persistent vomiting, severe abdominal pain, dehydration, or inability to keep fluids down. This is especially important because GLP-1-based medicines can affect gastrointestinal function and tolerability.6
What should patients know about GLP-1 safety and compounded medicines?
Licensed clinical review and pharmacy sourcing matter. GLP-1-based treatment can be helpful for some people, but it requires ongoing attention to side effects, medical history, and medication changes. Contact a clinician promptly for severe or persistent gastrointestinal symptoms, signs of dehydration, or other concerning symptoms.
FDA states that compounded GLP-1 drugs, including compounded semaglutide and tirzepatide, are not FDA-approved and do not undergo FDA review for safety, effectiveness, or quality before marketing.7 FDA also states that compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug, and that patients should obtain a prescription and use a state-licensed pharmacy.7 Avoid no-prescription sellers and products labeled for research use.
How can eligible patients explore semaglutide or tirzepatide at Chia?
At Chia, treatment begins with a 100% online clinical evaluation. You complete a short health questionnaire, then a licensed US provider reviews your information and may prescribe only when clinically appropriate. Prescriptions are never guaranteed.
We offer compounded semaglutide as an injection, with plans currently starting at $249 per month. We offer compounded tirzepatide as tablets, with plans currently starting at $249 per month, or injections, with plans currently starting at $299 per month. Microdosing plans are available for both treatments when a provider determines they are appropriate. Our partner pharmacies are US state-licensed 503A compounding pharmacies, and medications are shipped to the patient’s door.
| Chia treatment | Available forms | Current starting price | Clinical process |
|---|---|---|---|
| Compounded semaglutide | Injection | From $249/month | Provider-guided dosing; microdosing plans may be available when clinically appropriate. |
| Compounded tirzepatide | Tablets or injection | Tablets from $249/month; injection from $299/month | Provider-guided dosing; microdosing plans may be available when clinically appropriate. |
Our care team can adjust provider-guided treatment over time, and patients can message through the patient portal between visits. For more background before an evaluation, read our guide to microdosing tirzepatide.
What is the bottom line on GLP-1 vs. GLP-2 for weight loss?
GLP-1-based medicines belong in the weight-management conversation; GLP-2 medicines do not. Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on GIP and GLP-1 receptors.12 GLP-2 therapy has a separate role in intestinal care.10
The practical next step is not to self-select based on a hormone label. It is to have a licensed clinician review your health history, goals, current medicines, and potential risks. If you are comparing expected timelines, see what semaglutide studies can show over two months.
3-min quiz
Start with a clinical evaluation
If you are exploring GLP-1-based weight-management care, Chia offers an online, clinician-reviewed path to compounded semaglutide injection and compounded tirzepatide tablets or injections. A prescription depends on clinical review and is not guaranteed. Compounded medications are not FDA-approved; see our semaglutide and tirzepatide pages for current details and pricing.
Frequently asked questions about GLP-1 vs. GLP-2
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is not a GLP-2 medicine.2
GLP-2 therapy is used for specific intestinal conditions, not as established treatment for obesity or routine weight loss.10
Do not combine these medicines without a clinician who understands the reason for each treatment, your medical history, and your other medications. A GLP-2 medicine should not be added simply for weight loss; GLP-2 medicines are not established for weight loss.10
No. GLP-1 is a naturally occurring gut hormone. Semaglutide is a medicine that activates the GLP-1 receptor.6
References
- 1.Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
- 2.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- 3.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
- 4.Sandsdal RM, Juhl CR, Jensen SBK, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovascular Diabetology. 2023.
- 5.Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism. 2021.
- 6.StatPearls Publishing. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. 2024.
- 7.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Safety Communication. 2026.
- 8.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023.
- 9.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025.
- 10.Hsieh J, Longuet C, Baker CL, et al. GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Metabolism. Frontiers in Endocrinology. 2012.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
